Other OTC - Delayed Quote • USD
BioInvent International AB (publ) (BOVNF)
At close: July 29 at 12:25 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-328,668.0000
-341,691.0000
-41,227.0000
-245,843.0000
-62,622.0000
Investing Cash Flow
254,737.0000
59,681.0000
-628,848.0000
-467,542.0000
-6,700.0000
Financing Cash Flow
-7,971.0000
23,139.0000
273,487.0000
894,870.0000
644,617.0000
End Cash Position
460,614.0000
259,548.0000
515,047.0000
910,755.0000
729,270.0000
Capital Expenditure
-12,463.0000
-13,304.0000
-12,377.0000
-13,260.0000
-6,700.0000
Issuance of Capital Stock
--
30,959.0000
279,849.0000
900,794.0000
650,437.0000
Free Cash Flow
-341,131.0000
-354,995.0000
-53,604.0000
-259,103.0000
-69,322.0000
12/31/2020 - 9/3/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CASI CASI Pharmaceuticals, Inc.
2.4200
+5.22%
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
VYGR Voyager Therapeutics, Inc.
7.62
+2.70%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
CPRX Catalyst Pharmaceuticals, Inc.
14.89
+1.43%
AUPH Aurinia Pharmaceuticals Inc.
4.9100
+0.82%
ADMA ADMA Biologics, Inc.
6.55
+1.71%
MNKD MannKind Corporation
4.2300
+1.20%
ARDX Ardelyx, Inc.
6.42
+1.74%